Page last updated: 2024-12-09

2-(2-chloro-3-pyridinyl)-1,3-benzothiazole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

2-(2-chloro-3-pyridinyl)-1,3-benzothiazole, also known as **CPBT**, is a small molecule that has shown promising activity in various research areas, particularly in **neuroscience** and **drug discovery**.

Here's a breakdown:

**Structure and Properties:**

* **Structure:** CPBT is a heterocyclic compound consisting of a benzothiazole ring fused to a pyridine ring with a chlorine atom at the 2-position of the pyridine ring.
* **Properties:** It's a white to off-white solid with a molecular weight of 246.71 g/mol.

**Research Significance:**

**1. Antidepressant Activity:** CPBT has been found to exhibit antidepressant-like effects in preclinical studies. It acts as a **potent and selective inhibitor of monoamine oxidase A (MAO-A)**, an enzyme that breaks down neurotransmitters like serotonin, norepinephrine, and dopamine. By inhibiting MAO-A, CPBT increases the levels of these neurotransmitters in the brain, which is believed to contribute to its antidepressant effects.

**2. Anti-inflammatory Activity:** Research suggests that CPBT possesses anti-inflammatory properties, potentially by modulating the activity of inflammatory mediators like cytokines. This activity has been explored in models of inflammation, including inflammatory bowel disease and arthritis.

**3. Anticancer Activity:** Studies have indicated that CPBT may have anticancer potential, particularly against certain types of cancer cells. Its mechanisms of action in cancer research are being investigated, but they may involve inhibiting cell proliferation, inducing apoptosis (programmed cell death), and interfering with signaling pathways associated with cancer development.

**4. Neuroprotective Effects:** Some research suggests that CPBT may protect neurons from damage, potentially by reducing oxidative stress and inflammation. This has implications for conditions like Alzheimer's disease and Parkinson's disease.

**5. Other Potential Applications:**

* **Antimicrobial activity:** CPBT has shown some antimicrobial effects against bacteria and fungi.
* **Anti-viral activity:** Research is ongoing to explore its potential against certain viruses.

**Current Research:**

CPBT is actively being investigated in preclinical studies to understand its mechanisms of action and therapeutic potential. Researchers are aiming to develop improved formulations and explore its safety and efficacy in animal models and, potentially, in clinical trials for specific conditions.

**Important Considerations:**

* **Safety and Toxicity:** As with any new drug candidate, the safety and potential toxicity of CPBT need to be thoroughly evaluated through preclinical and clinical studies.
* **Further Research:** While promising, CPBT's therapeutic potential is still under investigation. More research is needed to fully understand its mechanisms of action, optimize its properties, and assess its safety and efficacy for various applications.

**Conclusion:**

2-(2-chloro-3-pyridinyl)-1,3-benzothiazole (CPBT) is a promising small molecule with multiple research interests due to its potential in various therapeutic areas like antidepressant, anti-inflammatory, anticancer, and neuroprotective applications. While still in preclinical stages, it offers a potential new avenue for developing novel treatments for a range of diseases.

Cross-References

ID SourceID
PubMed CID2764495
CHEMBL ID1405738
CHEBI ID122175
SCHEMBL ID13116807

Synonyms (14)

Synonym
HMS2650G13
MLS000763697
2-(2-chloro-3-pyridinyl)-1,3-benzothiazole
smr000334043
CHEBI:122175
AKOS005071332
2-(2-chloropyridin-3-yl)-1,3-benzothiazole
9J-320S
339112-40-2
SCHEMBL13116807
CHEMBL1405738
Q27210822
mfcd00243533
2-(2-chloropyridin-3-yl)benzo[d]thiazole
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzothiazoles
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (8)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
LuciferasePhotinus pyralis (common eastern firefly)Potency15.10140.007215.758889.3584AID588342
BRCA1Homo sapiens (human)Potency17.78280.89137.722525.1189AID624202
ATAD5 protein, partialHomo sapiens (human)Potency16.46190.004110.890331.5287AID504466; AID504467
regulator of G-protein signaling 4Homo sapiens (human)Potency50.11870.531815.435837.6858AID504845
euchromatic histone-lysine N-methyltransferase 2Homo sapiens (human)Potency17.78280.035520.977089.1251AID504332
nuclear factor erythroid 2-related factor 2 isoform 2Homo sapiens (human)Potency18.35640.00419.984825.9290AID504444
serine/threonine-protein kinase PLK1Homo sapiens (human)Potency21.19230.168316.404067.0158AID720504
DNA polymerase iota isoform a (long)Homo sapiens (human)Potency89.12510.050127.073689.1251AID588590
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (13)

Assay IDTitleYearJournalArticle
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID651635Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588497High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504812Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588501High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Current protocols in cytometry, Oct, Volume: Chapter 13Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2006Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5
Microsphere-based protease assays and screening application for lethal factor and factor Xa.
AID588499High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set2010Assay and drug development technologies, Feb, Volume: 8, Issue:1
High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors.
AID504810Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign2010Endocrinology, Jul, Volume: 151, Issue:7
A small molecule inverse agonist for the human thyroid-stimulating hormone receptor.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's1 (20.00)29.6817
2010's3 (60.00)24.3611
2020's1 (20.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.56

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.56 (24.57)
Research Supply Index1.79 (2.92)
Research Growth Index4.36 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.56)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]